A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study

Summary.Objective: To study the relative rates of progression of early Parkinson's disease (PD) in patients started on a dopamine agonist, ropinirole, or L-dopa. Methods: A double-blind study of 45 early PD patients [mean age 61 ± 9.8 SD and mean symptom duration, 26 ± 16 SD months] randomized 2 : 1 (ropinirole : L-dopa). Supplementary L-dopa was allowed if, during the trial, there was lack of a therapeutic effect. 18F-dopa PET scans were performed at baseline (n = 45) and 2 years (n = 37). Results: At two years, the mean percentage reduction in putamen 18F-dopa uptake (Kio) was not significantly different between the two groups (13% ropinirole, n = 28 versus 18% L-dopa, n = 9). Conclusions: We found no significant overall difference in underlying PD progression, after two years treatment, between patients groups. In summary, 18F-dopa PET can be employed to objectively evaluate the effect of potential neuroprotective agents on dopaminergic function.

[1]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[2]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[3]  F. Hefti,et al.  Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.

[4]  C. Patlak,et al.  Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.

[5]  C. Olanow,et al.  Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? , 1992, Neurology.

[6]  D J Brooks,et al.  Striatal dopaminergic function in restless legs syndrome , 1999, Neurology.

[7]  C. Shults.  Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease , 1993, Acta neurologica Scandinavica. Supplementum.

[8]  M. Youdim,et al.  Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.

[9]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[10]  H. Kimura,et al.  Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.

[11]  D B Calne,et al.  Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.

[12]  R. Badawi.  3D-mode acquisition in clinical PET. , 1997, Nuclear medicine communications.

[13]  S. Hirai,et al.  Dopa and dopamine cause cultured neuronal death in the presence of iron , 1991, Journal of the Neurological Sciences.

[14]  David L. Felten,et al.  Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats , 1992, Neurobiology of Aging.

[15]  Bernard Bendriem,et al.  Chapter 18 - Quantitation of the [ 18 F]Fluorodopa Uptake in the Human Striata in 3D PET with the ETM Scatter Correction , 1996 .

[16]  S R Meikle,et al.  A convolution-subtraction scatter correction method for 3D PET. , 1994, Physics in medicine and biology.

[17]  R. J. Eden,et al.  Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist , 1991, Pharmacology Biochemistry and Behavior.

[18]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[19]  P. Rosenberg,et al.  Iron‐Mediated Oxidation of 3,4‐Dihydroxyphenylalanine to an Excitotoxin , 1995, Journal of neurochemistry.

[20]  R. Hardie,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F] dopa PET , 1999, Journal of neurology, neurosurgery, and psychiatry.

[21]  M Schulzer,et al.  The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic , 1992, Annals of neurology.

[22]  David J. Brooks,et al.  Chapter 17 - Implementation of 3D Acquisition, Reconstruction, and Analysis of Dynamic [ 18 F]Fluorodopa Studies , 1996 .

[23]  T. Ishikawa,et al.  Fluorodopa Positron Emission Tomography with an Inhibitor of Catechol-O-Methyltransferase: Effect of the Plasma 3-O-Methyldopa Fraction on Data Analysis , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  M. Mena,et al.  Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid , 1993, Neuroreport.

[25]  M. Kohno,et al.  Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.

[26]  R. Roth,et al.  Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. , 1997, Cell transplantation.

[27]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[28]  S. Fahn,et al.  Neurotoxicity of levodopa on catecholamine‐rich neurons , 1992, Movement disorders : official journal of the Movement Disorder Society.

[29]  D. Bailey,et al.  3D acquisition and reconstruction in positron emission tomography , 1992, Annals of nuclear medicine.

[30]  M. Kawai,et al.  Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. , 1995, Archives internationales de pharmacodynamie et de therapie.

[31]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[32]  G. Sawle,et al.  The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism , 1994, Neurology.

[33]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[34]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[35]  M. Sasaki,et al.  Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms , 1996, Journal of the Neurological Sciences.

[36]  C. Nahmias,et al.  Dopamine visualized in the basal ganglia of living man , 1983, Nature.

[37]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[38]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[39]  N. Ogawa,et al.  Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist , 1999, Brain Research.

[40]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[41]  C D Marsden,et al.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.

[42]  J. Holden,et al.  Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.